This site is intended for healthcare professionals only
LoginRegister

NPPA sets ceiling prices of 14 formulations including Diabetes FDCs, details

Ruchika SharmaWritten by Ruchika Sharma   |  
NPPA sets ceiling prices of 14 formulations including Diabetes FDCs, details
  • whatsapp
  • Telegram

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority, the pharma price regulator has fixed the price of 14 formulations, including prominent diabetes FDCs.

Amoungst those whose price has been fixed include Remogliflozin Etabonate + Metformin Hydrochloride Tablets by M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd, Metformin Hydrochloride (As sustained release) and Vildagliptin Tablets of M/s Exemed Pharmaceuticals/ M/s Zydus Healthcare Limited as well as torrent pharma's Dapagliflozin + Metformin Hydrochloride Extended-Release Tablets

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl.

No.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer &

Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1.

Remogliflozin Etabonate + Metformin Hydrochloride Tablet

Each film coated tablet contains:

Remogliflozin Etabonate 100mg,

Metformin Hydrochloride IP 500mg

1 Tablet

M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.

11.44

2.

Remogliflozin Etabonate + Metformin Hydrochloride Tablet

Each film coated tablet contains:

Remogliflozin Etabonate 100mg,

Metformin Hydrochloride IP 1000mg

1 Tablet

M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.

13.18

3.

Aceclofenac + Paracetamol Tablet

Each film coated tablet contains:

Aceclofenac IP 100mg Paracetamol IP 325mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd.

4.23

4.

Atorvastatin + Aspirin Capsule

Each Hard Gelatin Capsule Contains:

Atorvastatin Calcium IP

1 Capsule

M/s Pure and Cure Healthcare Pvt. Ltd. / M/s

2.59

Sl.

No.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer &

Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

eq to Atorvastatin 10mg (As Film coated tablet form)

Aspirin IP 75mg (As Enteric Coated tablet form)

FDC Limited

5.

Thiocolchicoside + Aceclofenac + Paracetamol Tablet

Each film coated tablet contains: Thiocolchicoside IP 4mg Aceclofenac IP 100mg Paracetamol IP 325mg

1 Tablet

M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.

14.99

6.

Metformin Hydrochloride (As sustained release) and Vildagliptin Tablets

Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (As sustained release) 500mg,

Vildagliptin 50mg,

1 Tablet

M/s Exemed Pharmaceuticals

/ M/s Zydus Healthcare Limited

6.58

7.

Metformin Hydrochloride (As sustained release) and Vildagliptin Tablets

Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (As sustained release) 1000mg,

Vildagliptin 50mg,

1 Tablet

M/s Exemed Pharmaceuticals

/ M/s Zydus Healthcare Limited

7.07

8.

Metformin Hydrochloride (As sustained release) and Vildagliptin Tablets

Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (As sustained release) 500mg,

Vildagliptin 50mg,

1 Tablet

M/s Exemed Pharmaceuticals

/ M/s Lupin Limited

6.58

9.

Metformin Hydrochloride (As sustained release) and Vildagliptin Tablets

Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (As sustained release) 1000mg,

Vildagliptin 50mg,

1 Tablet

M/s Exemed Pharmaceuticals

/ M/s Lupin Limited

7.07

10.

Metronidazole and Dextrose Injection

Each 100ml contains: Metronidazole IP 0.2gm Dextrose IP (as anhydrous) 5.0 gm

Water for injection IP

Per 500ml Pack

M/s Aculife Healthcare Pvt. Ltd.

79.29

11.

Dapagliflozin + Metformin Hydrochloride Extended-Release Tablet

Each film-coated tablet contains:

Dapagliflozin 5mg, Metformin Hydrochloride IP (In Extended release

1 Tablet

M/s Torrent Pharmaceuticals Limited

6.97

Sl.

No.

Name of the

Formulation / Brand Name

Strength

Unit

Manufacturer &

Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

form) 500mg

12.

Dapagliflozin + Metformin Hydrochloride Extended-Release Tablet

Each film-coated tablet contains:

Dapagliflozin 5mg, Metformin Hydrochloride IP (In Extended release form) 1000mg

1 Tablet

M/s Torrent Pharmaceuticals Limited

8.35

Note:

(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a Price List in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display Price List and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
(Prasenjit Das)
Deputy Director
To view the official order, click on the following link:


nppanational pharmaceutical pricing authoritydrug pricesprice fixationretail price
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story
    X